Vaxcyte
Kevin Cun, CFA, is an accomplished finance professional with extensive experience in financial planning and analysis (FP&A) across various companies in the biotechnology sector. Currently serving as Senior Manager, FP&A at Vaxcyte since March 2023, Kevin previously held similar roles at Vir Biotechnology, Inc. and Chan Zuckerberg Biohub. Kevin's career began as an Assurance Senior Associate at EY, where responsibilities included auditing and staff training. Earlier experience includes financial roles at Theravance Biopharma US, Inc., where Kevin managed substantial budget preparations and operational finance processes. Kevin's academic background includes a Master of Accounting from the University of Southern California and dual Bachelor's degrees in Molecular Biology and Economics from UC San Diego, complemented by an Accounting Certificate.
This person is not in any teams
Vaxcyte
2 followers
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.